- Home
- QNCX vs PEPG Comparison
QNCX vs PEPG Comparison
Compare QNCX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- PEPG
- Stock Information
- Founded
- QNCX 2012
- PEPG 2018
- Country
- QNCX United States
- PEPG United States
- Employees
- QNCX N/A
- PEPG N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- PEPG Health Care
- Exchange
- QNCX Nasdaq
- PEPG Nasdaq
- Market Cap
- QNCX 47.7M
- PEPG 45.5M
- IPO Year
- QNCX 2019
- PEPG 2022
- Fundamental
- Price
- QNCX $1.59
- PEPG $1.23
- Analyst Decision
- QNCX Strong Buy
- PEPG Buy
- Analyst Count
- QNCX 5
- PEPG 3
- Target Price
- QNCX $8.00
- PEPG $7.67
- AVG Volume (30 Days)
- QNCX 353.3K
- PEPG 290.3K
- Earning Date
- QNCX 08-12-2025
- PEPG 08-07-2025
- Dividend Yield
- QNCX N/A
- PEPG N/A
- EPS Growth
- QNCX N/A
- PEPG N/A
- EPS
- QNCX N/A
- PEPG N/A
- Revenue
- QNCX N/A
- PEPG N/A
- Revenue This Year
- QNCX N/A
- PEPG N/A
- Revenue Next Year
- QNCX N/A
- PEPG N/A
- P/E Ratio
- QNCX N/A
- PEPG N/A
- Revenue Growth
- QNCX N/A
- PEPG N/A
- 52 Week Low
- QNCX $0.51
- PEPG $0.88
- 52 Week High
- QNCX $2.45
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- QNCX 64.95
- PEPG 41.13
- Support Level
- QNCX $1.48
- PEPG $1.05
- Resistance Level
- QNCX $1.68
- PEPG $1.49
- Average True Range (ATR)
- QNCX 0.14
- PEPG 0.10
- MACD
- QNCX 0.02
- PEPG -0.02
- Stochastic Oscillator
- QNCX 85.71
- PEPG 38.64
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.